Serum Soluble Receptors for Advanced Glycation End-Products May Predict Mortality in Microscopic Polyangiitis and Granulomatosis with Polyangiitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model. Results: The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094). Conclusion: This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA.
Abstract
Purpose: This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model. Results: The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094). Conclusion: This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA.
참고문헌 (31)
- Jennette JC, "2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides", Arthritis Rheum, 65, pp.1~11 (2013)
- Watts R, "Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies", Ann Rheum Dis, 66, pp.222~227 (2007)
- Robson JC, "2022 American College of Rheumatology", European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis, 2022, pp.81, 315~320
- Suppiah R, "2022 American College of Rheumatology", European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis, 2022, pp.81, 321~326
- Masiak A, "The usefulness of histopathological examinations of non-renal biopsies in the diagnosis of granulomatosis with polyangiitis", Reumatologia, 55, pp.230~236 (2017)
- Millet A, "Antineutrophil cytoplasmic antibody-associated vasculitides : is it time to split up the group?", Ann Rheum Dis, 72, pp.1273~1279 (2013)
- Yue Q, "Receptor for advanced glycation end products(RAGE) : a pivotal hub in immune diseases", Molecules, 27, pp.4922~ (2022)
- Riehl A, "The receptor RAGE : bridging inflammation and cancer", Cell Commun Signal, 7, pp.12~ (2009)
- Dong H, "Pathophysiology of RAGE in inflammatory diseases", Front Immunol, 13, pp.931473~ (2022)
- Moroz OV, "Multiple structural states of S100A12 : a key to its functional diversity", Microsc Res Tech, 60, pp.581~592 (2003)
- Page TH, "Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses", Rheumatology(Oxford), 61, pp.834~845 (2022)
- Bai X, "The potential pathogenic roles of S100A8", A9 and S100A12 in patients with MPO-ANCA-positive vasculitis, 2022, pp.23, 42~
- Erusalimsky JD, "The use of the soluble receptor for advanced glycation-end products(sRAGE)as a potential biomarker of disease risk and adverse outcomes", Redox Biol, 42, pp.101958~ (2021)
- Ahn SS, "Serological biomarkers and indices for the current activity and prognosis of ANCA-associated vasculitis : experience in a single centre in Korea", Yonsei Med J, 62, pp.279~287 (2021)
- Pyo JY, "Comparison of the 2022 ACR", EULAR classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis with previous criteria, 2023, pp.64, 11~17
- Mukhtyar C, "Modification and validation of the Birmingham vasculitis activity score(version 3)", Ann Rheum Dis, 68, pp.1827~1832 (2009)
- Guillevin L, "The five-factor score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group(FVSG)cohort", Medicine(Baltimore), 90, pp.19~27 (2011)
- Jafari Nakhjavani MR, "Relationship between serum-soluble receptor for advanced glycation end products(sRAGE)and disease activity in rheumatoid arthritis patients", Mod Rheumatol, 29, pp.943~948 (2019)
- Yilmaz Y, "Serum levels of soluble receptor for advanced glycation endproducts(sRAGE)are higher in ulcerative colitis and correlate with disease activity", J Crohns Colitis, 5, pp.402~406 (2011)
- Chen DY, "The potential role of advanced glycation end products(AGEs)and soluble receptors for AGEs(sRAGE)in the pathogenesis of adultonset still’s disease", BMC Musculoskelet Disord, 16, pp.111~ (2015)
- Serveaux-Dancer M, "Pathological implications of receptor for advanced glycation end-product(AGER)gene polymorphism", Dis Markers, 2019, pp.2067353~ (2019)
- Loomis SJ, "Cross-sectional analysis of AGE-CML, sRAGE, and esRAGE with diabetes and cardiometabolic risk factors in a community-based cohort", Clin Chem, 63, pp.980~989 (2017)
- Schmidt AM, "Soluble RAGEs—prospects for treating & tracking metabolic and inflammatory disease", Vascul Pharmacol, 72, pp.1~8 (2015)
- Basta G, "Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure", Liver Transpl, 21, pp.847~854 (2015)
- Murray CJ, "The state of US health, 1990-2010 : burden of diseases, injuries, and risk factors", JAMA, 310, pp.591~608 (2013)
- Tan JA, "Mortality in ANCA-associated vasculitis : ameta-analysis of observational studies", Ann Rheum Dis, 76, pp.1566~1574 (2017)
- Choi CB, "Antineutrophil cytoplasmic antibodyassociated vasculitis in Korea : a narrative review", Yonsei Med J, 60, pp.10~21 (2019)
- Pullerits R, "Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via β2 integrin Mac-1", Arthritis Rheum, 54, pp.3898~3907 (2006)
- Antonelli A, "The shedding-derived soluble receptor for advanced glycation endproducts sustains inflammation during acute Pseudomonas aeruginosa lung infection", Biochim Biophys Acta Gen Subj, 1861, pp.354~364 (2017)
- Sharifi-Zahabi E, "Circulating advanced glycation end products and their soluble receptors in relation to all-cause and cardiovascular mortality : a systematic review and meta-analysis of prospective observational studies", Adv Nutr, 12, pp.2157~2171 (2021)
- Kierdorf K, "RAGE regulation and signaling in inflammation and beyond", J Leukoc Biol, 94, pp.55~68 (2013)